Extending Rx Exclusivity Could Boost Study for Rare Diseases

Share this content:
Extending Rx Exclusivity Could Boost Study for Rare Diseases
Extending Rx Exclusivity Could Boost Study for Rare Diseases

MONDAY, Jan. 23, 2017 (HealthDay News) -- Extending the market exclusivity for existing drugs that are granted subsequent U.S. Food and Drug Administration (FDA) approval for a new rare disease indication would provide manufacturers with substantial compensation, often in excess of the cost of conducting the trials, according to research published in the January issue of Health Affairs.

Aaron S. Kesselheim, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues examined the economic impact of the proposal to encourage rare disease research by providing six months of extended exclusivity for any existing drug that is granted subsequent FDA approval for a new rare disease indication.

The researchers found that from 2005 through 2010, the median projected cost of clinical trials leading to approval was $29.8 million for the 13 FDA-approved drugs that gained supplemental approval for a rare disease indication. The median discounted financial gain to manufacturers would have been $94.6 million if the exclusivity extension had been in place. Median net returns would have been $82.4 million; drugs with higher annual sales would have had higher returns.

"Extending market exclusivity would provide substantial compensation to many manufacturers, particularly for top-selling products, far in excess of the cost of conducting these trials," the authors write. "Alternative strategies to incentivize the study of approved drugs for rare diseases may offer similar benefits at a lower cost."

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Cognitive Decline Similar After Cardiac Surgery, Catheterization

Cognitive Decline Similar After Cardiac Surgery, Catheterization

No subjective memory decline observed in association with cardiac surgery in older adults

Palliative Care in MS Inpatients Rises From 2005 to 2014

Palliative Care in MS Inpatients Rises From 2005 ...

Palliative care linked to increased length of stay and in-hospital death, decreased hospital charges

Psychosocial Factors Key in Peds Care for Special-Needs Kids

Psychosocial Factors Key in Peds Care for Special-Needs ...

Report provides guidance for clinicians caring for children and youth with special health care needs

is free, fast, and customized just for you!




Already a member?

Sign In Now »